Ocular Therapeutix, Inc financial data

Symbol
OCUL on Nasdaq
Industry
Pharmaceutical Preparations
Location
15 Crosby Drive, Bedford, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
I-THERAPEUTIX INC (to 7/2/2009)
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.46K % +233%
Quick Ratio 8.01 % +17%
Debt-to-equity 37.9 % -92.3%
Return On Equity -53.3 % +81.6%
Return On Assets -38.6 % +20.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 159M shares +6.99%
Common Stock, Shares, Outstanding 158M shares +37.2%
Entity Public Float 1.06B USD +162%
Common Stock, Value, Issued 16K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 158M shares +98.3%
Weighted Average Number of Shares Outstanding, Diluted 158M shares +84.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 63.7M USD +9.03%
Research and Development Expense 128M USD +109%
Selling and Marketing Expense 41.6M USD +2.57%
General and Administrative Expense 60.7M USD +78.7%
Costs and Expenses 236M USD +67.2%
Operating Income (Loss) -172M USD -109%
Nonoperating Income (Expense) -21.7M USD -1420%
Net Income (Loss) Attributable to Parent -194M USD -140%
Earnings Per Share, Basic -1.22 USD/shares -20.8%
Earnings Per Share, Diluted -1.22 USD/shares -19.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 392M USD +100%
Accounts Receivable, after Allowance for Credit Loss, Current 32.4M USD +23.7%
Inventory, Net 3.04M USD +31.9%
Assets, Current 441M USD +89.9%
Property, Plant and Equipment, Net 9.39M USD -20%
Operating Lease, Right-of-Use Asset 5.95M USD -8.14%
Assets 458M USD +81.7%
Accounts Payable, Current 4.18M USD -4.85%
Employee-related Liabilities, Current 14.3M USD +75%
Accrued Liabilities, Current 35.1M USD +22.5%
Contract with Customer, Liability, Current 128K USD -49.8%
Liabilities, Current 41.4M USD +18.5%
Contract with Customer, Liability, Noncurrent 14M USD -0.96%
Operating Lease, Liability, Noncurrent 5.35M USD -22.3%
Other Liabilities, Noncurrent 141K USD +30.6%
Liabilities 143M USD -11.4%
Retained Earnings (Accumulated Deficit) -891M USD -27.7%
Stockholders' Equity Attributable to Parent 315M USD +246%
Liabilities and Equity 458M USD +81.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.9M USD -69.7%
Net Cash Provided by (Used in) Financing Activities 321M USD +411724%
Net Cash Provided by (Used in) Investing Activities -255K USD +92.5%
Common Stock, Shares Authorized 400M shares +100%
Common Stock, Shares, Issued 158M shares +37.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 287M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 394M USD +99.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 13M USD +1750%
Deferred Tax Assets, Valuation Allowance 225M USD +22.6%
Deferred Tax Assets, Gross 229M USD +17.6%
Operating Lease, Liability 7.28M USD -14%
Payments to Acquire Property, Plant, and Equipment 255K USD -92.5%
Lessee, Operating Lease, Liability, to be Paid 8.74M USD -18.4%
Property, Plant and Equipment, Gross 33M USD +3.19%
Operating Lease, Liability, Current 1.93M USD +21.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.09M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.72M USD +8.71%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.46M USD -35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.18M USD -19.6%
Deferred Tax Assets, Operating Loss Carryforwards 135M USD +11.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 750K USD -64.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 920K USD +90.5%
Deferred Tax Assets, Net of Valuation Allowance 3.63M USD -66.5%
Share-based Payment Arrangement, Expense 33.1M USD +85.7%
Interest Expense 13.6M USD +91.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%